Mirum Completes Enrollment in Late-Stage EXPAND Study of Livmarli

MIRM completed enrollment in the Phase III EXPAND study of Livmarli targeting additional rare cholestatic liver diseases, with top-line data expected in Q4 2026. Enrollment completion reduces near-term development execution risk and keeps a pivotal readout on a multiyear timeline; commercial/valuation upside depends on the Q4 2026 efficacy and safety results.

Analysis

MIRM completed enrollment in the Phase III EXPAND study of Livmarli targeting additional rare cholestatic liver diseases, with top-line data expected in Q4 2026. Enrollment completion reduces near-term development execution risk and keeps a pivotal readout on a multiyear timeline; commercial/valuation upside depends on the Q4 2026 efficacy and safety results.